TScan Therapeutics, Inc.
TCRXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TCRX. That does not mean none is planned.
Get an email about TCRX's next catalysts
Track TScan Therapeutics (TCRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
TCRX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.18 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TSC-101 | Phase 3 | AML | - | - |
Frequently asked questions
What is in TScan Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in TScan Therapeutics, Inc.'s (TCRX) pipeline across Phase 3. Its lead program is TSC-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TScan Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for TScan Therapeutics, Inc. (TCRX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TCRX biotech catalysts?→
Add TCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TScan Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.